- Home
- GALT vs STIM Comparison
GALT vs STIM Comparison
Compare GALT & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- STIM
- Stock Information
- Founded
- GALT 2000
- STIM 2003
- Country
- GALT United States
- STIM United States
- Employees
- GALT N/A
- STIM N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- STIM Medical/Dental Instruments
- Sector
- GALT Health Care
- STIM Health Care
- Exchange
- GALT Nasdaq
- STIM Nasdaq
- Market Cap
- GALT 232.3M
- STIM 224.8M
- IPO Year
- GALT N/A
- STIM 2018
- Fundamental
- Price
- GALT $5.37
- STIM $3.13
- Analyst Decision
- GALT Strong Buy
- STIM Strong Buy
- Analyst Count
- GALT 3
- STIM 2
- Target Price
- GALT $6.00
- STIM $7.00
- AVG Volume (30 Days)
- GALT 301.1K
- STIM 1.5M
- Earning Date
- GALT 11-12-2025
- STIM 11-11-2025
- Dividend Yield
- GALT N/A
- STIM N/A
- EPS Growth
- GALT N/A
- STIM N/A
- EPS
- GALT N/A
- STIM N/A
- Revenue
- GALT N/A
- STIM $111,106,000.00
- Revenue This Year
- GALT N/A
- STIM $105.70
- Revenue Next Year
- GALT N/A
- STIM $11.77
- P/E Ratio
- GALT N/A
- STIM N/A
- Revenue Growth
- GALT N/A
- STIM 54.17
- 52 Week Low
- GALT $0.73
- STIM $0.52
- 52 Week High
- GALT $6.55
- STIM $5.92
- Technical
- Relative Strength Index (RSI)
- GALT 68.40
- STIM 39.89
- Support Level
- GALT $3.93
- STIM $3.00
- Resistance Level
- GALT $4.35
- STIM $3.71
- Average True Range (ATR)
- GALT 0.38
- STIM 0.27
- MACD
- GALT 0.10
- STIM 0.02
- Stochastic Oscillator
- GALT 55.47
- STIM 17.61
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About STIM Neuronetics Inc.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.